Literature DB >> 27648914

Tetrapeptide Endomorphin Analogs Require Both Full Length and Truncated Splice Variants of the Mu Opioid Receptor Gene Oprm1 for Analgesia.

Gina F Marrone1,2, Zhigang Lu1, Grace Rossi3, Ankita Narayan1,2, Amanda Hunkele1, Sarah Marx1, Jin Xu1, John Pintar4, Susruta Majumdar1, Ying-Xian Pan1, Gavril W Pasternak1,2.   

Abstract

The mu opioid receptor gene undergoes extensive alternative splicing. Mu opioids can be divided into three classes based on the role of different groups of splice variants. Morphine and methadone require only full length seven transmembrane (7TM) variants for analgesia, whereas IBNtxA (3'-iodobenzyol-6β-naltrexamide) needs only truncated 6TM variants. A set of endomorphin analogs fall into a third group that requires both 6TM and 7TM splice variants. Unlike morphine, endomorphin 1 and 2, DAPP (Dmt,d-Ala-Phe-Phe-NH2), and IDAPP (3'-iodo-Dmt-d-Ala-Phe-Phe-NH2) analgesia was lost in an exon 11 knockout mouse lacking 6TM variants. Restoring 6TM variant expression in a knockout mouse lacking both 6TM and 7TM variants failed to rescue DAPP or IDAPP analgesia. However, re-establishing 6TM expression in an exon 11 knockout mouse that still expressed 7TM variants did rescue the response, consistent with the need for both 6TM and 7TM variants. In receptor binding assays, 125I-IDAPP labeled more sites (Bmax) than 3H-DAMGO ([d-Ala2,N-MePhe4,Gly(ol)5]-enkephalin) in wild-type mice. In exon 11 knockout mice, 125I-IDAPP binding was lowered to levels similar to 3H-DAMGO, which remained relatively unchanged compared to wild-type mice. 125I-IDAPP binding was totally lost in an exon 1/exon 11 knockout model lacking all Oprm1 variant expression, confirming that the drug was not cross labeling non-mu opioid receptors. These findings suggested that 125I-IDAPP labeled two populations of mu binding sites in wild-type mice, one corresponding to 7TM variants and the second dependent upon 6TM variants. Together, these data indicate that endomorphin analogs represent a unique, genetically defined, and distinct class of mu opioid analgesic.

Entities:  

Keywords:  G-Protein coupled receptor; Mu opioid receptor; alternative splicing; analgesia; endorphin; morphine

Mesh:

Substances:

Year:  2016        PMID: 27648914      PMCID: PMC5177531          DOI: 10.1021/acschemneuro.6b00240

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  50 in total

Review 1.  Controlling the pain of cancer.

Authors:  K M Foley
Journal:  Sci Am       Date:  1996-09       Impact factor: 2.142

2.  Acute antinociceptive tolerance and asymmetric cross-tolerance between endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse.

Authors:  H E Wu; K C Hung; H Mizoguchi; J M Fujimoto; L F Tseng
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

Review 3.  The genetic mediation of individual differences in sensitivity to pain and its inhibition.

Authors:  J S Mogil
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

4.  Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2.

Authors:  K Monory; M C Bourin; M Spetea; C Tömböly; G Tóth; H W Matthes; B L Kieffer; J Hanoune; A Borsodi
Journal:  Eur J Neurosci       Date:  2000-02       Impact factor: 3.386

5.  Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse.

Authors:  S Sakurada; T Hayashi; M Yuhki; T Orito; J E Zadina; A J Kastin; T Fujimura; K Murayama; C Sakurada; T Sakurada; M Narita; T Suzuki; K Tan-no; L F Tseng
Journal:  Eur J Pharmacol       Date:  2001-09-21       Impact factor: 4.432

6.  Pharmacokinetics and pharmacodynamics of subcutaneous morphine pellets in the rat.

Authors:  B C Yoburn; J Chen; T Huang; C E Inturrisi
Journal:  J Pharmacol Exp Ther       Date:  1985-11       Impact factor: 4.030

7.  Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.

Authors:  Y A Kolesnikov; C G Pick; G Ciszewska; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

Review 8.  Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management.

Authors:  Folabomi A Oladosu; William Maixner; Andrea G Nackley
Journal:  Mayo Clin Proc       Date:  2015-08       Impact factor: 7.616

9.  Separation of morphine analgesia from physical dependence.

Authors:  G S Ling; J M MacLeod; S Lee; S H Lockhart; G W Pasternak
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

10.  Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone-related protein in the rat.

Authors:  J A Schetz; C A Mayr; J E Taylor; M Rosenblatt; M Chorev; T P Davis
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

View more
  4 in total

Review 1.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.

Authors:  Balazs R Varga; John M Streicher; Susruta Majumdar
Journal:  Br J Pharmacol       Date:  2021-11-26       Impact factor: 9.473

Review 2.  Interactive Mechanisms of Supraspinal Sites of Opioid Analgesic Action: A Festschrift to Dr. Gavril W. Pasternak.

Authors:  Grace C Rossi; Richard J Bodnar
Journal:  Cell Mol Neurobiol       Date:  2020-09-24       Impact factor: 5.046

3.  Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom.

Authors:  Soumen Chakraborty; Rajendra Uprety; Amal E Daibani; Valerie L Rouzic; Amanda Hunkele; Kevin Appourchaux; Shainnel O Eans; Nitin Nuthikattu; Rahul Jilakara; Lisa Thammavong; Gavril W Pasternak; Ying-Xian Pan; Jay P McLaughlin; Tao Che; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2021-07-02       Impact factor: 5.780

Review 4.  Exploring Pharmacological Functions of Alternatively Spliced Variants of the Mu Opioid Receptor Gene, Oprm1, via Gene-Targeted Animal Models.

Authors:  Wenjian Kang; Shan Liu; Jin Xu; Anna Abrimian; Ayma F Malik; Raymond Chien; Adejuyigbe Adaralegbe; Akwasi Amponsah; Luca Cartegni; John Pintar; Ying-Xian Pan
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.